Brief: Actinium Presents Data From Phase 3 SIERRA Trial
25/04/2022 12:37
April 25 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES 82% OF CONTROL
ARM
PATIENTS DID NOT RECEIVE A BONE MARROW TRANSPLANT BY
CONVENTIONAL MEANS BUT 100% OF PATIENTS WHO RECEIVED IOMAB-B,
INCLUDING CROSSOVER PATIENTS, IN THE PHASE 3 SIERRA TRIAL
SUCCESSFULLY ENGRAFTED AT THE TRANSPLANTATION & CELLULAR THERAPY
TANDEM MEETINGS OF ASTCT AND CIBMTR
Source text for Eikon: ID:nPn96RnKLa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities